CO7400878A2 - Anticuerpos anti-mcam y métodos de uso asociados - Google Patents
Anticuerpos anti-mcam y métodos de uso asociadosInfo
- Publication number
- CO7400878A2 CO7400878A2 CO15077895A CO15077895A CO7400878A2 CO 7400878 A2 CO7400878 A2 CO 7400878A2 CO 15077895 A CO15077895 A CO 15077895A CO 15077895 A CO15077895 A CO 15077895A CO 7400878 A2 CO7400878 A2 CO 7400878A2
- Authority
- CO
- Colombia
- Prior art keywords
- mcam
- associated methods
- mcam antibodies
- antibodies
- antigen
- Prior art date
Links
- PJOHVEQSYPOERL-SHEAVXILSA-N (e)-n-[(4r,4as,7ar,12br)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a-yl]-3-(4-methylphenyl)prop-2-enamide Chemical compound C1=CC(C)=CC=C1\C=C\C(=O)N[C@]1(CCC(=O)[C@@H]2O3)[C@H]4CC5=CC=C(O)C3=C5[C@]12CCN4CC1CC1 PJOHVEQSYPOERL-SHEAVXILSA-N 0.000 abstract 2
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 abstract 2
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698916P | 2012-09-10 | 2012-09-10 | |
| US201261797179P | 2012-11-30 | 2012-11-30 | |
| US201261797356P | 2012-12-05 | 2012-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7400878A2 true CO7400878A2 (es) | 2015-09-30 |
Family
ID=50237783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO15077895A CO7400878A2 (es) | 2012-09-10 | 2015-04-08 | Anticuerpos anti-mcam y métodos de uso asociados |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US20150239980A1 (enExample) |
| EP (2) | EP2892562B1 (enExample) |
| JP (1) | JP6339574B2 (enExample) |
| KR (1) | KR102194568B1 (enExample) |
| CN (2) | CN105120895A (enExample) |
| AR (1) | AR092488A1 (enExample) |
| AU (2) | AU2013312203B2 (enExample) |
| CA (1) | CA2884463A1 (enExample) |
| CL (1) | CL2015000582A1 (enExample) |
| CO (1) | CO7400878A2 (enExample) |
| CU (1) | CU20150023A7 (enExample) |
| DK (1) | DK2892562T3 (enExample) |
| EA (1) | EA201590528A1 (enExample) |
| ES (1) | ES2718208T3 (enExample) |
| IL (1) | IL237625A0 (enExample) |
| MX (1) | MX2015002918A (enExample) |
| MY (1) | MY182427A (enExample) |
| PE (1) | PE20151286A1 (enExample) |
| PH (1) | PH12015500514A1 (enExample) |
| SG (2) | SG10201708127UA (enExample) |
| TW (3) | TWI595007B (enExample) |
| WO (1) | WO2014039975A2 (enExample) |
| ZA (1) | ZA201501858B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2568436T3 (es) | 2006-03-31 | 2016-04-29 | Chugai Seiyaku Kabushiki Kaisha | Procedimiento para controlar la farmacocinética en sangre de anticuerpos |
| BRPI0817294A2 (pt) | 2007-09-26 | 2015-03-17 | Chugai Pharmaceutical Co Ltd | Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr. |
| EP3056513A1 (en) | 2008-04-11 | 2016-08-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| KR102568454B1 (ko) | 2010-11-30 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| EP2889376A4 (en) | 2012-08-24 | 2016-11-02 | Chugai Pharmaceutical Co Ltd | MOUSE FC RII SPECIFIC FC ANTIBODY |
| TW202237660A (zh) | 2012-08-24 | 2022-10-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗ｍｃａｍ抗體及相關使用方法 |
| WO2014163101A1 (ja) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Ｆｃ領域改変体 |
| WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| TW201623331A (zh) * | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
| EP3116910A1 (en) * | 2014-03-13 | 2017-01-18 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
| US20170216409A1 (en) * | 2014-08-05 | 2017-08-03 | The University Of Chicago | Modulation of laminin alpha-4 in the prevention, treatment, and management of metabolic syndromes |
| EP4600372A3 (en) | 2014-12-19 | 2025-11-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| CN104725483A (zh) * | 2015-04-06 | 2015-06-24 | 苏州普罗达生物科技有限公司 | 一种黑色素瘤细胞粘附分子拮抗剂多肽及其应用 |
| CN104710513A (zh) * | 2015-04-06 | 2015-06-17 | 苏州普罗达生物科技有限公司 | 黑色素瘤细胞粘附分子拮抗剂多肽及其应用 |
| CA2998716A1 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017046774A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| EP3387442A4 (en) | 2015-12-09 | 2019-05-08 | Corvus Pharmaceuticals, Inc. | HUMANIZED ANTI-CD73 ANTIBODIES |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE |
| WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2017153953A1 (en) * | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
| WO2018223140A1 (en) * | 2017-06-02 | 2018-12-06 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| CA3087058A1 (en) * | 2017-12-26 | 2019-07-04 | The Regents Of The University Of California | Human antibodies that bind and are internalized by mesothelioma and other cancer cells |
| CN117447599A (zh) | 2018-12-21 | 2024-01-26 | 普众发现医药科技(上海)有限公司 | 对muc18特异性的抗体 |
| AU2019401657B2 (en) * | 2018-12-21 | 2025-10-09 | Multitude Therapeutics Inc. | Antibodies specific to MUC18 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| EP4627096A1 (en) | 2022-12-02 | 2025-10-08 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| CN121443743A (zh) | 2023-05-23 | 2026-01-30 | 赛纳生物技术公司 | 串联融合剂和相关脂质颗粒 |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| GB1520819A (en) | 1976-05-10 | 1978-08-09 | Robertson H J | Medical protein hydrolysate process of making the same and processes of utilizing the protein hydrolysate to aid in healing traumatized areas |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5224539A (en) | 1991-06-14 | 1993-07-06 | Coen Company, Inc. | Cooling system for air heaters and the like |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| GB9406974D0 (en) | 1994-04-08 | 1994-06-01 | Pharmaceutical Proteins Ltd | Transgenic production |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| AU757961B2 (en) | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US7192931B2 (en) | 2000-10-12 | 2007-03-20 | Neuren Pharmaceuticals Ltd. | Treatment of demyelinating diseases |
| US6866866B1 (en) | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
| AU2002252444A1 (en) | 2001-03-23 | 2002-10-08 | Board Of Regents, The University Of Texas System | Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors |
| AU2002354784A1 (en) | 2001-07-03 | 2003-01-21 | Sciperio, Inc. | Methods and systems for embedding electrical components in a device including a frequency responsive structure |
| TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| WO2003057838A2 (en) * | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Antibodies against the muc18 antigen |
| JP2005514409A (ja) | 2001-12-28 | 2005-05-19 | アブジェニックス・インコーポレーテッド | Ｍｕｃ１８抗原に対する抗体の使用 |
| JP2005516965A (ja) * | 2001-12-28 | 2005-06-09 | アブジェニックス・インコーポレーテッド | 抗ｍｕｃ１８抗体を使用する方法 |
| JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| US7456260B2 (en) | 2002-06-17 | 2008-11-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Humanized antibody |
| EP2365004B1 (en) * | 2002-06-21 | 2016-01-06 | Johns Hopkins University School of Medicine | Membrane associated tumor endothelium markers |
| EP1382615A1 (en) * | 2002-07-15 | 2004-01-21 | Xerion Pharmaceuticals AG | MCAM inhibitors |
| MXPA05007843A (es) | 2003-01-24 | 2005-10-18 | Elan Pharm Inc | Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes. |
| UY28886A1 (es) * | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
| AU2005287406B2 (en) * | 2004-07-26 | 2011-08-18 | Biogen Ma Inc. | Anti-CD154 antibodies |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2007058725A2 (en) * | 2005-10-12 | 2007-05-24 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
| AU2006323415A1 (en) * | 2005-12-06 | 2007-06-14 | Domantis Limited | Bispecific ligands with binding specificity to cell surface targets and methods of use therefor |
| WO2009028663A1 (ja) | 2007-08-30 | 2009-03-05 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-3抗体 |
| WO2009054435A1 (ja) | 2007-10-24 | 2009-04-30 | Otsuka Chemical Co., Ltd. | 増強されたエフェクター機能を有するポリペプチド |
| JP5745854B2 (ja) | 2007-11-13 | 2015-07-08 | テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド | Ｔｌ１ａに対するヒト化抗体 |
| EP2234600B1 (en) | 2007-12-21 | 2014-08-20 | F. Hoffmann-La Roche AG | Antibody formulation |
| US8155019B2 (en) * | 2008-01-07 | 2012-04-10 | Canon Kabushiki Kaisha | Information processing apparatus, device information display method, and computer-readable storage medium |
| AR070141A1 (es) | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | Anticuerpos humanizados especificos para el factor von willebrand |
| US8293468B2 (en) | 2009-06-10 | 2012-10-23 | Centre Hospitalier De L'université De Montréal | MCAM modulation and uses thereof |
| JP5858785B2 (ja) * | 2009-07-29 | 2016-02-10 | シスメックス株式会社 | ヒトｉｌ−１７産生ヘルパーｔ細胞検出用マーカーおよび試薬、並びにヒトｉｌ−１７産生ヘルパーｔ細胞の検出方法 |
| WO2011100477A2 (en) * | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| NZ602734A (en) | 2010-03-02 | 2014-10-31 | Abbvie Inc | Therapeutic dll4 binding proteins |
| US8501418B2 (en) | 2010-08-06 | 2013-08-06 | Pronata N.V. | Method of treating renal dysfunction based on perlecan as a biomarker |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| SG190877A1 (en) | 2010-11-25 | 2013-07-31 | Allecra Therapeutics Gmbh | Compounds and their use |
| JP5946605B2 (ja) * | 2011-01-28 | 2016-07-06 | シスメックス株式会社 | ヒトｉｌ−１７産生ヘルパーｔ細胞の検出方法 |
| US20140314744A1 (en) | 2011-06-06 | 2014-10-23 | Neotope Biosciences Limited | Mcam antagonists and methods of treatment |
| US10316095B2 (en) | 2012-02-16 | 2019-06-11 | Santarus, Inc. | Antibody formulations |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗ｍｃａｍ抗體及相關使用方法 |
| KR102109053B1 (ko) | 2013-10-24 | 2020-05-13 | 아스트라제네카 아베 | 안정한 수성 항체 제제 |
| WO2015136570A1 (ja) | 2014-03-11 | 2015-09-17 | パナソニック液晶ディスプレイ株式会社 | 表示装置及びその駆動方法 |
| KR20160131082A (ko) | 2014-03-12 | 2016-11-15 | 프로테나 바이오사이언시즈 리미티드 | Lg1-3에 특이적인 항-라미닌4 항체 |
| WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
| US20170129954A1 (en) | 2014-03-12 | 2017-05-11 | Prothena Biosciences Limited | Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis |
| US20170101470A1 (en) | 2014-03-12 | 2017-04-13 | Prothena Biosciences Limited | Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis |
| EP3116910A1 (en) | 2014-03-13 | 2017-01-18 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
| CA2998716A1 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2018223140A1 (en) | 2017-06-02 | 2018-12-06 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
-
2013
- 2013-09-06 TW TW102132203A patent/TWI595007B/zh not_active IP Right Cessation
- 2013-09-06 TW TW106116728A patent/TWI660972B/zh not_active IP Right Cessation
- 2013-09-06 TW TW108108483A patent/TW201922795A/zh unknown
- 2013-09-09 EA EA201590528A patent/EA201590528A1/ru unknown
- 2013-09-09 SG SG10201708127UA patent/SG10201708127UA/en unknown
- 2013-09-09 US US14/427,290 patent/US20150239980A1/en not_active Abandoned
- 2013-09-09 AU AU2013312203A patent/AU2013312203B2/en not_active Ceased
- 2013-09-09 DK DK13836030.0T patent/DK2892562T3/en active
- 2013-09-09 EP EP13836030.0A patent/EP2892562B1/en active Active
- 2013-09-09 US US14/021,777 patent/US9447190B2/en not_active Expired - Fee Related
- 2013-09-09 CN CN201380047188.9A patent/CN105120895A/zh active Pending
- 2013-09-09 MY MYPI2015700717A patent/MY182427A/en unknown
- 2013-09-09 MX MX2015002918A patent/MX2015002918A/es unknown
- 2013-09-09 EP EP19155167.0A patent/EP3530287A1/en not_active Withdrawn
- 2013-09-09 WO PCT/US2013/058773 patent/WO2014039975A2/en not_active Ceased
- 2013-09-09 CA CA2884463A patent/CA2884463A1/en not_active Abandoned
- 2013-09-09 PE PE2015000328A patent/PE20151286A1/es not_active Application Discontinuation
- 2013-09-09 ES ES13836030T patent/ES2718208T3/es active Active
- 2013-09-09 JP JP2015531286A patent/JP6339574B2/ja not_active Expired - Fee Related
- 2013-09-09 KR KR1020157008706A patent/KR102194568B1/ko not_active Expired - Fee Related
- 2013-09-09 SG SG11201501773RA patent/SG11201501773RA/en unknown
- 2013-09-09 CN CN201710411450.3A patent/CN107266571A/zh active Pending
- 2013-09-09 AR ARP130103202A patent/AR092488A1/es unknown
-
2015
- 2015-03-09 IL IL237625A patent/IL237625A0/en unknown
- 2015-03-09 CL CL2015000582A patent/CL2015000582A1/es unknown
- 2015-03-10 CU CUP2015000023A patent/CU20150023A7/es unknown
- 2015-03-10 PH PH12015500514A patent/PH12015500514A1/en unknown
- 2015-03-18 ZA ZA2015/01858A patent/ZA201501858B/en unknown
- 2015-04-08 CO CO15077895A patent/CO7400878A2/es unknown
-
2016
- 2016-07-28 US US15/222,848 patent/US10407507B2/en not_active Expired - Fee Related
- 2016-07-28 US US15/222,849 patent/US10414825B2/en not_active Expired - Fee Related
-
2017
- 2017-10-05 US US15/726,170 patent/US10584177B2/en not_active Expired - Fee Related
-
2018
- 2018-10-04 AU AU2018241135A patent/AU2018241135B2/en not_active Ceased
-
2020
- 2020-01-16 US US16/745,178 patent/US20200216560A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7400878A2 (es) | Anticuerpos anti-mcam y métodos de uso asociados | |
| MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
| CO2018006299A2 (es) | Compuestos novedosos | |
| CO7151531A2 (es) | Anticuerpos e inmunoconjugados contra ly6e y métodos de uso | |
| CR20120522A (es) | Pirrolobenzodiacepinas y conjugados de las mismas | |
| PH12015502293A1 (en) | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use | |
| CO7020867A2 (es) | Formulaciones de anticuerpo y metodos | |
| AR083044A1 (es) | Anticuerpos anti-cd48 y usos de los mismos | |
| CO6721041A2 (es) | Anticuerpo anti-pcsk9 y métodos de uso | |
| EA201390254A1 (ru) | Модифицированные полипептиды релаксина и их применение | |
| ECSP13012673A (es) | Métodos y composiciones para inmunoterapia para enfermedad neural | |
| MX2016003744A (es) | Anticuerpos tem8 y su uso. | |
| CL2015003135A1 (es) | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso. | |
| TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
| EA201790664A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
| EP2566890A4 (en) | ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE | |
| MX370597B (es) | Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer. | |
| CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
| PE20161092A1 (es) | Anticuerpos especificos para el ligando 1a tipo factor de necrosis tumoral y composiciones y uso de ellos | |
| EA201592269A1 (ru) | Способы и композиции для снижения иммуносупрессии опухолевыми клетками | |
| CR20140212A (es) | Anticuerpos anti-htra1 y métodos de uso | |
| MX2012011718A (es) | Anticuerpos anti-erbb3. | |
| BR112017006468A2 (pt) | anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer | |
| NZ604510A (en) | Dilutable biocidal compositions and methods of use | |
| MX2019000641A (es) | Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso. |